Last $3.59 USD
Change Today +0.01 / 0.28%
Volume 3.0M
EXEL On Other Exchanges
As of 5:20 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

exelixis inc (EXEL) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $8.41
52 Week Low
04/15/14 - $3.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EXELIXIS INC (EXEL)

exelixis inc (EXEL) Related Businessweek News

No Related Businessweek News Found

exelixis inc (EXEL) Details

Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

227 Employees
Last Reported Date: 02/20/14
Founded in 1994

exelixis inc (EXEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $681.7K
Executive Vice President of Exelixis
Total Annual Compensation: $617.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $577.3K
Total Annual Compensation: $689.2K
Compensation as of Fiscal Year 2013.

exelixis inc (EXEL) Key Developments

Exelixis, Inc. Announces Positive Top-Line Results from coBRIM

Exelixis, Inc. announced positive top-line results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring the BRAF(V600) mutation. Exelixis' collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its primary endpoint, delivering a statistically significant increase in progression-free survival (PFS) for the combination of cobimetinib plus vemurafenib as compared to vemurafenib alone. Adverse events were consistent with those observed in a previous study of the combination. Genentech will present these coBRIM data at an upcoming medical meeting and plans to initiate regulatory filings before year end. In addition to the coBRIM results just announced, Exelixis anticipates delivering on the following key clinical development initiatives before the end of 2014: Top-line results from pivotal phase 3 studies COMET-1 (overall survival endpoint) and COMET-2 (pain palliation endpoint) of cabozantinib in metastatic castration-resistant prostate cancer; Top-line results from the overall survival analysis of EXAM, the phase 3 pivotal trial of cabozantinib in progressive, metastatic medullary thyroid cancer; and completing enrollment in METEOR, the phase 3 pivotal trial of cabozantinib in metastatic renal cell cancer.

Exelixis, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-10-2014 09:20 AM

Exelixis, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-10-2014 09:20 AM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Michael M. Morrissey, Chief Executive Officer, President and Director.

Exelixis, Inc. Announces Management Changes, Effective from June 2, 2014

Exelixis, Inc. and Frank Karbe, the company’s Executive Vice President and Chief Financial Officer, have entered into a transition and consulting agreement dated May 7, 2014 and effective as of May 2, 2014 pursuant to which Mr. Karbe’s employment with the company will cease on June 2, 2014. The company has initiated a search to fill the position of Chief Financial Officer with a candidate who possesses significant experience in the global commercialization of biopharmaceutical products. Effective on the transition date, Deborah Burke, the company’s Vice President, Finance and Controller, will assume the role of interim Chief Financial Officer (and in such capacity, as the company’s interim principal financial officer and interim principal accounting officer, as defined under applicable securities laws) until a permanent replacement is named.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEL:US $3.59 USD +0.01

EXEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $5.10 USD -0.05
Array BioPharma Inc $3.93 USD +0.04
CrystalGenomics Inc 16,050 KRW -50.00
CTI BioPharma Corp $2.66 USD -0.08
Evotec AG €3.73 EUR +0.071
View Industry Companies

Industry Analysis


Industry Average

Valuation EXEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.8x
Price/Book 9.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXELIXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at